Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)

Gaurav N. Pathaka Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey;b Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North CarolinaCorrespondence[email protected]

https://orcid.org/0000-0002-8383-4451 View further author information

Anurag N. Pathakc Department of Computer Science, Rutgers University School of Arts and Sciences, New Brunswick, New JerseyView further author information

Vibha Mitala Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Piscataway, New JerseyView further author information

Jimmy Dhillona Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Piscataway, New JerseyView further author information

Steven R. Feldmanb Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina;d Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina;e Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina;f Department of Dermatology, University of Southern Denmark, Odense, Denmark

https://orcid.org/0000-0002-0090-6289 View further author information

Babar K. Raoa Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey;g Department of Dermatology, Rao Dermatology, Atlantic Highlands, New JerseyView further author information

Click to increase image sizeClick to decrease image size

Data availability

All data sources utilized in this study are publicly available.

Disclosure statement

Feldman has received research, speaking and/or consulting support from AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Eurofins, Forte, Galderma, Helsinn, Janssen, Leo Pharma, Micreos, Mylan, Novartis, Ono, Ortho Dermatology, Pfizer, Regeneron, Samsung, Sanofi, Sun Pharma, UCB, Verrica, Voluntis, and vTv Therapeutics. He is founder and part owner of Causa Research and holds stock in Sensal Health. Rao is a speaker for Incyte and Amgen. All other authors have no conflicts of interest to declare.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)

Information for

Open access

Opportunities

Help and information

Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)

Data availability

Disclosure statement

Additional information

Funding

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature